Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Ffrench, Brendan ^a,b   Gasch, Claudia ^a,b   O'Leary, John J ^a,b   Gallagher, Michael F ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b Pathology Research Laboratory   (Ireland)

Author keywords

Aldehyde dehydrogenase; Cancer stem cells; Clonal cancer stemness; Cluster of differentiation (CD) proteins; Hoechst; Ovarian cancer; Proliferate to kill; Stem cell models

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; FLUOROURACIL; GEMCITABINE; HERMES ANTIGEN; HOE 33342; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 5; MYELOID DIFFERENTIATION FACTOR 88; NOTCH RECEPTOR; PROTEIN MAD2; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL CLONE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL INVASION; CELL ISOLATION; CELL PROLIFERATION; CELL SUBPOPULATION; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOPOIETIC STEM CELL; HOLOCLONE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEROCLONE; METASTASIS; NONHUMAN; OVARY CANCER; PARACLONE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPHEROID CELL; TUMOR XENOGRAFT;

EID: 84928793104     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-262     Document Type: Review

References (108)

1. Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 1, 177:1053-1064. 10.2353/ajpath.2010.100105
2. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 1, 414:105-111. 10.1038/35102167
3. Andrews PW: From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci 1, 357:405-417. 10.1098/rstb.2002.1058
4. Kleinsmith LJ, Pierce GB: Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964, 24:1544-1551.
5. Andrews PW: Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 1, 103:285-293. 10.1016/0012-1606(84)90316-6
6. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1, 3:730-737. 10.1038/nm0797-730
7. Josephson R, Ording CJ, Liu Y, Shin S, Lakshmipathy U, Toumadje A, Love B, Chesnut JD, Andrews PW, Rao MS, Auerbach JM: Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells Dayt Ohio 1, 25:437-446. 10.1634/stemcells.2006-0236
8. Cheung TH, Rando TA: Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol 1, 14:329-340. 10.1038/nrm3591
9. Alert . Nature 2014, 510:393-408.
10. Beerman I, Seita J, Inlay AM, Weissman IL, Rossi DJ: Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 1, 15:37-50. 10.1016/j.stem.2014.04.016
11. Fossett N: Signal transduction pathways, intrinsic regulators, and the control of cell fate choice. Biochim Biophys Acta 1830, 2013:2375-2384.
12. Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H: TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 1, 113:1250-1256. 10.1182/blood-2008-04-146480
13. Alison MR, Guppy NJ, Lim SML, Nicholson LJ: Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol 1, 222:335-344. 10.1002/path.2772
14. Williams K, Motiani K, Giridhar PV, Kasper S: CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med Maywood NJ 1, 238:324-338. 10.1177/1535370213480714
15. Golebiewska A, Brons NHC, Bjerkvig R, Niclou SP: Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 1, 8:136-147. 10.1016/j.stem.2011.01.007
16. Bapat SA: Human ovarian cancer stem cells. Reprod Camb Engl 2010, 140:33-41.
17. Flesken-Nikitin A, Hwang C-I, Cheng C-Y, Michurina TV, Enikolopov G, Nikitin AY: Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 1, 495:241-245. 10.1038/nature11979
18. Zheng W, Fadare O: Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Pathol 2012, 5:182-186.
19. Burgos-Ojeda D, Rueda BR, Buckanovich RJ: Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 1, 322:1-7. 10.1016/j.canlet.2012.02.002
20. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur M-H, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 1, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741
21. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 1, 69:3382-3389. 10.1158/0008-5472.CAN-08-4418
22. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, Strazzer S, Bresolin N, Comi GP: Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells Dayt Ohio 1, 24:975-985. 10.1634/stemcells.2005-0217
23. Ma S, Chan KW, Lee TK-W, Tang KH, Wo JY-H, Zheng B-J, Guan X-Y: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res MCR 1, 6:1146-1153. 10.1158/1541-7786.MCR-08-0035
24. Sullivan JP, Minna JD, Shay JW: Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 1, 29:61-72. 10.1007/s10555-010-9216-5
25. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 1, 71:3991-4001. 10.1158/0008-5472.CAN-10-3175
26. Duester G: Alcohol dehydrogenase as a critical mediator of retinoic acid synthesis from vitamin A in the mouse embryo. J Nutr 1998,128(2 Suppl):459S-462S.
27. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 1, 9:3186-3199. 10.1158/1535-7163.MCT-10-0563
28. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W: Expression of ALDH and CD133 defines ovarian cancer stem cells. Int J Cancer J Int Cancer 1, 130:29-39. 10.1002/ijc.25967
29. Wang Y-C, Yo Y-T, Lee H-Y, Liao Y-P, Chao T-K, Su P-H, Lai H-C: ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 1, 180:1159-1169. 10.1016/j.ajpath.2011.11.015
30. Shi MF, Jiao J, Lu WG, Ye F, Ma D, Dong QG, Xie X: Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci CMLS 1, 67:3915-3925. 10.1007/s00018-010-0420-9
31. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ: Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 1, 7:e29079. 10.1371/journal.pone.0029079
32. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells Dayt Ohio 2009, 27:2875-2883.
33. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE: Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A 1, 108:6468-6473. 10.1073/pnas.1005529108
34. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 1, 28:209-218. 10.1038/onc.2008.374
35. Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, Zhu B: Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9 upregulation. Stem Cells Dayt Ohio 1, 30:2309-2319. 10.1002/stem.1194
36. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 1, 103:11154-11159. 10.1073/pnas.0603672103
37. Hu L, McArthur C, Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 1, 102:1276-1283. 10.1038/sj.bjc.6605626
38. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 1, 35:227-234. 10.1042/CBI20100347
39. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L, Rocconi RP: CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 1, 29:939-948. 10.1007/s10585-012-9482-4
40. Zhang S, Balch C, Chan MW, Lai H-C, Matei D, Schilder JM, Yan PS, Huang TH-M, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 1, 68:4311-4320. 10.1158/0008-5472.CAN-08-0364
41. Gao M-Q, Choi Y-P, Kang S, Youn JH, Cho N-H: CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 1, 29:2672-2680. 10.1038/onc.2010.35
42. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1, 183:1797-1806. 10.1084/jem.183.4.1797
43. Bleau A-M, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 1, 4:226-235. 10.1016/j.stem.2009.01.007
44. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells Dayt Ohio 1, 24:506-513. 10.1634/stemcells.2005-0282
45. Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 1, 67:4827-4833. 10.1158/0008-5472.CAN-06-3557
46. Chiba T, Kita K, Zheng Y-W, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatol Baltim Md 1, 44:240-251. 10.1002/hep.21227
47. Human Cluster of Differentiation Molecules. [ http://www.hcdm.org ]
48. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 1, 275:5512-5520. 10.1074/jbc.275.8.5512
49. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 1, 445:106-110. 10.1038/nature05372
50. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 1, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018
51. Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB: A cell surface chondroitin sulfate proteoglycan, immunologically related to CD1, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992, 116:521-531. 10.1083/jcb.116.2.521
52. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer J Int Cancer 1, 120:1444-1450. 10.1002/ijc.22476
53. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
54. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 1:313-323. 10.1016/j.stem.2007.06.002
55. Kusumbe AP, Mali AM, Bapat SA: CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells Dayt Ohio 1, 27:498-508. 10.1634/stemcells.2008-0868
56. Hough MR, Rosten PM, Sexton TL, Kay R, Humphries RK: Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics 1, 22:154-161. 10.1006/geno.1994.1356
57. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 1, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030
58. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 1, 100:3983-3988. 10.1073/pnas.0530291100
59. Lesley J, Hyman R: CD44 structure and function. Front Biosci J Virtual Libr 1998, 3:d616-d630.
60. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci 1, 39:527-579. 10.1080/10408360290795574
61. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A: CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1, 128:687-698. 10.1083/jcb.128.4.687
62. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1, 31:1037-1051. 10.1016/S1357-2725(99)00076-X
63. Canonico B, Felici C, Papa S: CD117. J Biol Regul Homeost Agents 2001, 15:90-94.
64. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG: Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 1, 25:1696-1708. 10.1038/sj.onc.1209327
65. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, Zhang P, Santana-Lemos BA, Neuberg D, Wagers AJ, Rego EM, Tenen DG: Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 1, 114:5415-5425. 10.1182/blood-2008-10-182071
66. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 1, 70:4602-4612. 10.1158/0008-5472.CAN-09-3463
67. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 1, 100:15178-15183. 10.1073/pnas.2036535100
68. Svendsen CN, ter Borg MG, Armstrong RJ, Rosser AE, Chandran S, Ostenfeld T, Caldwell MA: A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 1, 85:141-152. 10.1016/S0165-0270(98)00126-5
69. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, Fodstad O, Lorico A: Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 1, 314:2110-2122. 10.1016/j.yexcr.2008.03.008
70. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, Cufi S, Pavon A, Menendez JA, Dopazo J, Martin AG: Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One 1, 8:e77281. 10.1371/journal.pone.0077281
71. Liu K-C, Yo Y-T, Huang R-L, Wang Y-C, Liao Y-P, Huang T-S, Chao T-K, Lin C-K, Weng S-J, Ma K-H, Chang C-C, Yu M-H, Lai H-C: Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget 2013, 4:2366-2382.
72. Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, Odunsi K: Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 1, 9:e84941. 10.1371/journal.pone.0084941
73. Tan L, Sui X, Deng H, Ding M: Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 1, 6:e23383. 10.1371/journal.pone.0023383
74. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG: PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 1, 68:1820-1825. 10.1158/0008-5472.CAN-07-5878
75. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22:255-288.
76. Auersperg N: The origin of ovarian cancers-hypotheses and controversies. Front Biosci Sch Ed 2013, 5:709-719.
77. D' Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LAJ, Sheils O, O'Toole S, O'Leary JJ: The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS One 1, 9:e100816. 10.1371/journal.pone.0100816
78. Kelly MG, Alvero AB, Chen R, Silasi D-A, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 1, 66:3859-3868. 10.1158/0008-5472.CAN-05-3948
79. Silasi D-A, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu H-H, Schwartz P, Rutherford T, Azodi M, Mor G: MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 2006, 79:153-163.
80. Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A: Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol 1, 226:746-755. 10.1002/path.3035
81. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J, Li K: Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in Ovarian Cancer: A Meta-Analysis. PLoS One 2013,8(11):e81050. 10.1371/journal.pone.0081050
82. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang L-P, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Bützow R, Coukos G, Zhang L: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 1, 5:e10277. 10.1371/journal.pone.0010277
83. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J: CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol Off J U S Can Acad Pathol Inc 2012, 25:456-464.
84. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 1, 133:704-715. 10.1016/j.cell.2008.03.027
85. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV: Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 1, 335:41-51. 10.1016/j.canlet.2013.01.054
86. McAuliffe SM, Morgan AL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng K, Dragett J, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM: Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2014,109(43):E2939-E2948.
87. Chen K, Huang Y, Chen J: Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 1, 34:732-740. 10.1038/aps.2013.27
88. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojťsek B, Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer J Int Cancer 1, 55:678-684. 10.1002/ijc.2910550428
89. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56:556-562.
90. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med Camb Mass 1995, 1:506-526.
91. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK: Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 1, 105:1485-1495. 10.1093/jnci/djt210
92. Liu H, Dibling B, Spike B, Dirlam A, Macleod K: New roles for the RB tumor suppressor protein. Curr Opin Genet Dev 1, 14:55-64. 10.1016/j.gde.2003.11.005
93. Laios A, O'Toole SA, Flavin R, Martin C, Ring M, Gleeson N, D'Arcy T, McGuinness EP, Sheils O, Sheppard BL, O' Leary JJ: An integrative model for recurrence in ovarian cancer. Mol Cancer 1, 7:8. 10.1186/1476-4598-7-8
94. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 1, 7:35. 10.1186/1476-4598-7-35
95. Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ: Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 1, 2:19. 10.1186/1757-2215-2-19
96. Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, Flavin RJ, Elbaruni SA, Spillane CD, Martin CM, Sheils OM, O'Leary JJ: Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovarian Res 1, 5:2. 10.1186/1757-2215-5-2
97. Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, MacLaughlin DT, Donahoe PK: Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A 1, 107:18874-18879. 10.1073/pnas.1012667107
98. Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, Mor G: TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle Georget Tex 1, 12:511-521. 10.4161/cc.23406
99. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 1, 146:873-887. 10.1016/j.cell.2011.08.039
100. Harrison DE, Lerner CP: Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 1991, 78:1237-1240.
101. Kim J, Hwangbo J, Wong PKY: p38 MAPK-Mediated Bmi-1 down-regulation and defective proliferation in ATM-deficient neural stem cells can be restored by Akt activation. PLoS One 1, 6:e16615. 10.1371/journal.pone.0016615
102. Arsenijevic Y, Weiss S, Schneider B, Aebischer P: Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. J Neurosci Off J Soc Neurosci 2001, 21:7194-7202.
103. Crouch MF, Davy DA, Willard FS, Berven LA: Insulin induces epidermal growth factor (EGF) receptor clustering and potentiates EGF-stimulated DNA synthesis in swiss 3 T3 cells: a mechanism for costimulation in mitogenic synergy. Immunol Cell Biol 1, 78:408-414. 10.1046/j.1440-1711.2000.00929.x
104. Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B: Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133(+) cancer stem-like cells in ovarian cancer. Oncogene 2013. doi:10.1038/onc.2013.537
105. Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol Off J Eur Soc Med Oncol ESMO 1, 18:945-949. 10.1093/annonc/mdl499
106. Ahmed N, Stenvers KL: Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 2013, 3:256.
107. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, Rogers D: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 1, 336:688-690. 10.1038/336688a0
108. Ying QL, Nichols J, Chambers I, Smith A: BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 1, 115:281-292. 10.1016/S0092-8674(03)00847-X